Veracyte Q4 Revenues Up 15 Percent on Higher Afirma Gene Expression Classifier Volume | GenomeWeb

NEW YORK (GenomeWeb) — Veracyte announced after the close of the market Thursday a 15 percent rise in fourth quarter revenues amid strong growth in demand for the company's Afirma gene expression classifier (GEC) test.

For the three-month period ended Dec. 31, Veracyte's revenues climbed to $14 million from $12.2 million in the same period the year before, falling short of analysts' consensus estimate of $14.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.

Sponsored by
Agilent Technologies

In this online seminar, speakers from the Center for Personalized Diagnostics at Penn Medicine will discuss the design and technical validation of a custom next-generation sequencing panel to detect mutations in a wide array of tumor types.